Novo Fights To Nix Counterclaims In Prandin IP Suit

Law360, New York (August 18, 2009, 1:42 PM EDT) -- In Novo Nordisk Inc.'s suit seeking to block a generic version of diabetes treatment Prandin, the drugmaker has asked a federal judge to toss allegations by Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. that it concealed clinical trial reports to patent officials.

On Monday, Novo requested that the U.S. District Court for the Eastern District of Michigan grant it partial summary adjudication on the defendants’ claims that it committed inequitable conduct by failing to disclose seven Novo-sponsored clinical trial reports to the U.S. Patent...
To view the full article, register now.